Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Lymphoid Malignancy Risk with Rare Inherited Variants in Known Cancer Predisposition Genes

Blood (2023) 142 (Supplement 1): 2990.

https://doi.org/10.1182/blood-2023-182266

Published: 2023

Journal Articles

Diagnosis to Treatment Interval (DTI) Informs Outcomes across Subtypes of Aggressive B-Cell Lymphoma

Matthew J. Maurer, Arushi Khurana, Raphael Mwangi, Grzegorz S. Nowakowski, Carla Casulo, Dai Chihara, Jonathon B. Cohen, Brad S. Kahl, Izidore S. Lossos, Peter Martin, Yucai Wang, Timothy J. McDonnell, Andrew L. Feldman, David L Jaye, Thomas M. Habermann, James R. Cerhan, Christopher R. Flowers, Brian K. Link, Loretta J. Nastoupil

Blood (2023) 142 (Supplement 1): 3123.

https://doi.org/10.1182/blood-2023-174715

Published: 2023

Journal Articles

Molecular Classification of Relapsed DLBCL Reveals Novel Biologic Subgroups

Blood (2023) 142 (Supplement 1): 2770.

https://doi.org/10.1182/blood-2023-180949

Published: 2023

Journal Articles

Primary Central Nervous System Lymphoma and Contemporary Clinical Prognostication

Richard C. Godby, Steven R. Hwang, Brianna Gysbers, Raphael Mwangi, Matthew J. Maurer, Thomas E. Witzig, Jonas Paludo, J. C. Villasboas, Urshila Durani, Thomas M. Habermann, Grzegorz S. Nowakowski, Arushi Khurana, Patrick B Johnston

Blood (2023) 142 (Supplement 1): 1768.

https://doi.org/10.1182/blood-2023-182866

Published: 2023

Journal Articles

Comparing Clinical Characteristics and Outcomes of MYC and BCL6 Double Hit Lymphoma (DHL- BCL6 ) with Other Aggressive B-Cell Lymphomas: Understanding the Impact of New Who and International Consensus Classifications

Blood (2023) 142 (Supplement 1): 67.

https://doi.org/10.1182/blood-2023-190316

Published: 2023

Journal Articles

Comparison of Methotrexate Maintenance Versus Autologous Stem Cell Transplant Consolidation after High-Dose Methotrexate-Based Induction Therapy in Primary Central Nervous System Lymphoma

Steven R Hwang, Patrick B Johnston, Richard C. Godby, Brianna Gysbers, Raphael Mwangi, Ivana Micallef, Stephen M Ansell, Luis Porrata, Urshila Durani, Gita Thanarajasingam, Matthew J. Maurer, Thomas M. Habermann, Arushi Khurana

Blood (2023) 142 (Supplement 1): 989.

https://doi.org/10.1182/blood-2023-178081

Published: 2023

Journal Articles

Artificial Intelligence Derived Changes between Baseline and Interim FDG-PET/CT Radiomics Features Are Associated with Survival Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL)

Jacob Shreve, Allison M. Bock, Izel Okcu, Antonious Hazim, Joshua C Pritchett, Raphael Mwangi, Matthew J. Maurer, Mithun V Shah, Yucai Wang, Stephen M Ansell, Thomas M. Habermann, Thomas E. Witzig, James R. Cerhan, Jason R Young, Moritz Binder, Grzegorz S. Nowakowski, Jonas Paludo

Blood (2023) 142 (Supplement 1): 5026.

https://doi.org/10.1182/blood-2023-190958

Published: 2023

Journal Articles

Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era

Sanjal H Desai, Raphael Mwangi, Yucai Wang, Umar Farooq, Eric Mou, Andrew L. Feldman, Sergei Syrbu, Susan L. Slager, Grzegorz S. Nowakowski, Matthew J. Maurer, Neil E. Kay, Thomas M. Habermann, Brian K. Link, Carrie A. Thompson, James R. Cerhan

Blood (2022) 140 (Supplement 1): 1934–1936.

https://doi.org/10.1182/blood-2022-165207

Published: 2022

Journal Articles

Dose Intensity and Reasons for Dose Alterations in Patients Excluded from Frontline Diffuse Large B-Cell Lymphoma Clinical Trials Based on Eligibility Criteria: A Mayo Clinic Cohort Study

Arushi Khurana, Raphael Mwangi, Rebecca L. King, Thomas M. Habermann, Stephen M. Ansell, James R. Cerhan, Grzegorz S. Nowakowski, Thomas E. Witzig, Matthew J. Maurer

Blood (2022) 140 (Supplement 1): 6666–6667.

https://doi.org/10.1182/blood-2022-169575

Published: 2022

Journal Articles

Prediction of Early Disease Progression at 24 Months (POD24) Using Pre-Treatment Biopsies from Patients with Follicular Lymphoma (FL) Treated with Immunochemotherapy (IC)

George W. Wright, Colleen A. Ramsower, James R. Cerhan, Anne J. Novak, Brian K. Link, Matthew J. Maurer, Raphael Mwangi, Allison C. Rosenthal, Thomas M. Habermann, Lou Staudt, Robert Kridel, David W. Scott, Christian Steidl, Lisa M. Rimsza

Blood (2022) 140 (Supplement 1): 6426–6427.

https://doi.org/10.1182/blood-2022-160351

Published: 2022

Journal Articles

Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis

Arushi Khurana, Raphael Mwangi, Loretta J. Nastoupil, Patrick M. Reagan, Umar Farooq, Jason T. Romancik, Timothy J. McDonnell, Shaun M Riska, Izidore S. Lossos, Brad S. Kahl, Peter Martin, Thomas E. Witzig, James R. Cerhan, Christopher R. Flowers, Matthew J. Maurer, Grzegorz S. Nowakowski

Blood (2022) 140 (Supplement 1): 2056–2058.

https://doi.org/10.1182/blood-2022-169433

Published: 2022

Journal Articles

Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL

Blood (2022) 140 (Supplement 1): 1742–1744.

https://doi.org/10.1182/blood-2022-159620

Published: 2022

Journal Articles

PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts

Sanjal H Desai, Levi D. Pederson, Betsy Laplant, Raphael Mwangi, Matthew J. Maurer, Jason R. Young, William R. Macon, Rebecca L. King, Yucai Wang, James R. Cerhan, Andrew L. Feldman, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski

Blood (2021) 138 (Supplement 1): 2508.

https://doi.org/10.1182/blood-2021-151276

Published: 2021

Journal Articles

Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes

Allison M. Bock, Raphael Mwangi, Matthew J. Maurer, Nora Bennani, David J. Inwards, James R. Cerhan, Thomas E. Witzig, Thomas M. Habermann, Yucai Wang, Grzegorz S. Nowakowski

Blood (2021) 138 (Supplement 1): 2524.

https://doi.org/10.1182/blood-2021-146206

Published: 2021

Journal Articles

Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab

Allison C. Rosenthal, Colleen Ramsower, Raphael Mwangi, Matthew J. Maurer, Diego Villa, Timothy J. McDonnell, Andrew L. Feldman, Thomas M. Habermann, Jonathon B. Cohen, Ryan S. Robetorye, Elías Campo, Eva Giné, James R. Cook, Brian T. Hill, Philipp Raess, German Ott, Alexander Reichart, David W. Scott, Lisa M. Rimsza

Blood (2021) 138 (Supplement 1): 3517.

https://doi.org/10.1182/blood-2021-151275

Published: 2021

Journal Articles

Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Xavier Andrade-Gonzalez, Raphael Mwangi, Jithma P. Abeykoon, Paul J. Hampel, Saurabh Zanwar, Betsy Laplant, Gita Thanarajasingam, Umar Farooq, Matthew J. Maurer, Thomas E. Witzig, Thomas M. Habermann, Jose C. Villasboas, Anne J. Novak

Blood (2021) 138 (Supplement 1): 1439.

https://doi.org/10.1182/blood-2021-151973

Published: 2021

Journal Articles

Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era

Aung M Tun, MD, Raphael Mwangi, Brian K. Link, MD, Andrew L. Feldman, MD, Matthew J. Maurer, MS, Thomas E. Witzig, MD, Carrie A. Thompson, MD, Anne J. Novak, PhD, Jose C Villasboas, MD, Umar Farooq, MD, Sergei Syrbu, MD PhD, James R. Cerhan, MD PhD, Thomas M. Habermann, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-139814

Published: 2020

Journal Articles

Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis

Arushi Khurana, MBBS, Raphael Mwangi, Stephen M. Ansell, MD PhD, Thomas M. Habermann, MD, James R. Cerhan, MD PhD, Christopher Strouse, MD, Brian K. Link, MD, Yucai Wang, MDPhD, Rebecca L. King, MD, William R. Macon, MD, Jose C Villasboas, MD, Thomas E. Witzig, MD, Matthew J. Maurer, MS, Grzegorz S. Nowakowski, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141011

Published: 2020

Journal Articles

Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts

Michelle J. Cox, Charles J. Kuhlmann, Rosalie M. Sterner, Reona Sakemura, MD PhD, Sutapa Sinha, PhD, Raphael Mwangi, MS, Nancy Scott, MS, Mehrdad Hefazi, MD, Omar Ahmed, Dale Chappell, Cameron Durrant, Claudia Manriquez Roman, Kendall J. Schick, Erin E. Tapper, Paulina Horvei, MD, Michael W. Ruff, MD, Sameer A. Parikh, MD, Neil E. Kay, MD, Saad S. Kenderian, MD

Blood (2019) 134 (Supplement_1): 3868.

https://doi.org/10.1182/blood-2019-129349

Published: 2019

NARROW

Lymphoid Malignancy Risk with Rare Inherited Variants in Known Cancer Predisposition Genes

Diagnosis to Treatment Interval (DTI) Informs Outcomes across Subtypes of Aggressive B-Cell Lymphoma

Molecular Classification of Relapsed DLBCL Reveals Novel Biologic Subgroups

Primary Central Nervous System Lymphoma and Contemporary Clinical Prognostication

Comparing Clinical Characteristics and Outcomes of MYC and BCL6 Double Hit Lymphoma (DHL- BCL6 ) with Other Aggressive B-Cell Lymphomas: Understanding the Impact of New Who and International Consensus Classifications

Comparison of Methotrexate Maintenance Versus Autologous Stem Cell Transplant Consolidation after High-Dose Methotrexate-Based Induction Therapy in Primary Central Nervous System Lymphoma

Artificial Intelligence Derived Changes between Baseline and Interim FDG-PET/CT Radiomics Features Are Associated with Survival Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL)

Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era

Dose Intensity and Reasons for Dose Alterations in Patients Excluded from Frontline Diffuse Large B-Cell Lymphoma Clinical Trials Based on Eligibility Criteria: A Mayo Clinic Cohort Study

Prediction of Early Disease Progression at 24 Months (POD24) Using Pre-Treatment Biopsies from Patients with Follicular Lymphoma (FL) Treated with Immunochemotherapy (IC)

Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis

Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL

PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts

Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes

Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab

Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era

Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis

Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only